Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Worldwide Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$13,935,011

161 payments

Through program year 2025, Worldwide Clinical Trials is reported as receiving $13,935,011 in research payments, across 161 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $475,647 6
2024 Research $186,589 4
2023 Research $1,288,978 14
2022 Research $1,882,923 27
2021 Research $5,320,456 26
2020 Research $2,923,247 44
2019 Research $1,857,170 40

Breakdown

Who paid Research payments · program years 2019–2025
  1. Deciphera Pharmaceuticals Inc. $2,561,551 20 payments
  2. Mitsubishi Tanabe Pharma Development America, Inc. $2,154,958 2 payments
  3. Indivior Inc. $1,682,016 20 payments
  4. Otonomy, Inc. $1,681,593 31 payments
  5. Merck Sharp & Dohme Corporation $1,667,537 16 payments
  6. Mallinckrodt LLC $1,134,956 18 payments
  7. CutisPharma, Inc. $990,924 7 payments
  8. Braintree Laboratories, Inc. $847,245 17 payments
  9. AbbVie, Inc. $471,377 5 payments
  10. Neos Therapeutics, LP $451,798 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1 Study to Evaluate the Pharmacokinetics of Dcc-3014 in Healthy Adult Participants $2,557,072 14 payments
  2. A Phase I, Open-Label, Four-Part, Single-Sequence Study to Investigate Drug-Drug Interaction Between Mt-7117 and Test Drugs in Healthy Subjects $1,731,044 1 payment
  3. A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Subjective Tinnitus $1,681,593 31 payments
  4. A Phase I Double-Blind, Placebo-Controlled Randomized Study to Assess Repeated Doses of Indv-2000 (C4x_3256) Up to 28 Days in Healthy Volunteers, and An Open-Label Study of Indv-2000 Up to 11 Days in Treatment Seeking Individuals With Opioid Use Disorder $1,350,315 12 payments
  5. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-RangingTrial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults $1,223,572 3 payments
  6. Bli4701-101 $617,634 8 payments
  7. ALIA-1758-101 Ph 1 SAD Study $448,238 2 payments
  8. A Study to Assess the Effect of Food on the Pharmacokinetics of the MK-6482 Final Market Image Tablet Formulation in Healthy Participants $432,595 5 payments
  9. Safety and Efficacy Study of MT-2990 in Women With Endometriosis $423,914 1 payment
  10. A single-dose, single-center, open-label, randomized, 5-arm, parallel study to assess the systematic exposure and safety of four modified-release orally disintegrating tablet formulations of NT0502 (N-desethyloxybutynin) and oxybutynin in healthy adults under fasted conditions - 4008579 (NT0502-1001) $299,248 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record